Tigecycline's Mechanism on Liver Function
Tigecycline, a glycylcycline antibiotic, inhibits bacterial protein synthesis by binding the 30S ribosomal subunit. Its impact on liver function primarily involves hepatic metabolism and transport disruption, rather than direct enzyme inhibition for therapeutic effects. Tigecycline undergoes extensive hepatic uptake and biliary excretion, with minimal cytochrome P450 (CYP450) involvement—it's not a substrate, inhibitor, or inducer of major CYP enzymes (e.g., CYP3A4, CYP1A2, CYP2C9).[1][2]
Key Enzymes in Tigecycline Metabolism
- Organic anion-transporting polypeptides (OATPs): OATP1B1 (SLCO1B1) and OATP1B3 mediate hepatic uptake. Tigecycline is a substrate, and elevated levels from transport issues can contribute to cholestasis-like liver injury.[3]
- Bile salt export pump (BSEP, ABCB11): Involved in biliary excretion; tigecycline weakly inhibits BSEP, potentially causing intrahepatic cholestasis, a reported hepatotoxicity pattern.[4]
- Multidrug resistance-associated protein 2 (MRP2, ABCC2): Facilitates efflux into bile; polymorphisms or inhibition link to tigecycline accumulation and elevated liver enzymes (ALT/AST).[5]
No primary CYP enzymes drive its clearance; ~59% is excreted unchanged in bile/feces.[2]
Clinical Liver Effects and Enzyme Links
Tigecycline causes asymptomatic transaminase elevations in 1-13% of patients, with rare severe cases (e.g., cholestatic hepatitis, DILI Network score >3).[6] Risk rises with high doses (>100 mg/day) or prolonged use. Liver function impacts tie to OATP/BSEP inhibition, mimicking patterns in other antibiotics like rifampin. Monitoring AST/ALT/bilirubin is standard; discontinue if >5x ULN.[7]
Factors Influencing Liver Risk
- Genetic variants: SLCO1B1*5 reduces uptake, increasing exposure and ALT risk.[3]
- Drug interactions: Avoid with strong OATP inhibitors (e.g., cyclosporine), amplifying hepatotoxicity.[1]
- Patient groups: Higher incidence in ICU/hepatic impairment patients; dose-adjust for Child-Pugh C (25 mg BID).[2]
Alternatives with Lower Liver Impact
| Drug | Key Liver Enzymes | Hepatotoxicity Rate |
|------|-------------------|---------------------|
| Tigecycline | OATP1B1/1B3, BSEP | 1-13% transaminitis |
| Meropenem | Minimal CYP/OATP | <1% |
| Vancomycin | Renal clearance | <2% (rare DILI) |
| Linezolid | Oxidative metabolism (non-CYP) | 0.5-3% |
Meropenem or vancomycin often preferred for similar indications (e.g., complicated infections) with less hepatic burden.[8]
Sources
[1]: FDA Tigecycline Label
[2]: DrugPatentWatch.com - Tigecycline
[3]: Clin Pharmacol Ther - SLCO1B1 and Tigecycline
[4]: Hepatology - BSEP Inhibition by Antibiotics
[5]: Pharmacogenet Genomics - MRP2 Variants
[6]: LiverTox - Tigecycline
[7]: IDSA Guidelines - Tigecycline Use
[8]: J Antimicrob Chemother - Comparative Safety